Skip to main content
. Author manuscript; available in PMC: 2022 Mar 1.
Published in final edited form as: J Cyst Fibros. 2021 Feb 19;20(2):205–212. doi: 10.1016/j.jcf.2021.02.003

Figure 1.

Figure 1.

Organ systems being evaluated in the PROMISE study.

A wide range of organ systems and disease manifestations are being studied during the multi-year observational period. This will allow us to better understand the impacts of ETI therapy in clinical use and where it may be most beneficial to focus or prioritize ongoing therapeutic and research goals in those treated with highly effective modulator drugs.